Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Becton Dickinson ( (BDX) ) is now available.
Effective October 1, 2025, BD reorganized its operations into five global business segments—BD Medical Essentials, BD Connected Care, BD BioPharma Systems, BD Interventional and BD Life Sciences—aligning distinct product and service lines such as medication delivery, specimen management, medication management, advanced patient monitoring, biopharma systems, urology and critical care, peripheral intervention, surgery and life sciences under separately managed strategic units. The company also disclosed that its Biosciences and Diagnostic Solutions businesses, which currently comprise the Life Sciences segment, are subject to a definitive agreement signed on July 13, 2025, to be combined with Waters Corporation, after which Life Sciences will be removed from BD’s segment reporting, and it has provided recast historical segment revenues and related non-GAAP revenue metrics to help investors assess performance and comparability under the new structure.
The most recent analyst rating on (BDX) stock is a Buy with a $233.00 price target. To see the full list of analyst forecasts on Becton Dickinson stock, see the BDX Stock Forecast page.
Spark’s Take on BDX Stock
According to Spark, TipRanks’ AI Analyst, BDX is a Neutral.
The score is driven primarily by stable financial performance (healthy margins, improving leverage, and strong cash generation) and a generally positive—but cautious—FY26 earnings outlook with clear margin and cost actions. This is tempered by a neutral technical picture in the near term and a relatively high valuation (P/E 34.72) that reduces upside if growth slows under the cited headwinds.
To see Spark’s full report on BDX stock, click here.
More about Becton Dickinson
Becton Dickinson and Company (BD) is a global medical technology firm that develops, manufactures and markets a broad range of medical devices, diagnostic products and laboratory equipment. Its operations span medication delivery and management, specimen collection, interventional products and life sciences tools, serving healthcare providers, biopharmaceutical companies and clinical laboratories worldwide.
Average Trading Volume: 2,130,639
Technical Sentiment Signal: Buy
Current Market Cap: $59.22B
See more insights into BDX stock on TipRanks’ Stock Analysis page.